8-K filings / November 20, 2026
Compass Therapeutics, Inc.: A stock exchange listing notice
Compass Therapeutics, Inc. filed a current report (Form 8-K) with the SEC on November 20, 2026. It reports a stock exchange listing notice.
AI-written from the facts below
In plain English
On November 19, 2026, the company received a notice from Nasdaq concerning its stock exchange listing. In the notice, Nasdaq states that the company does not meet a listing rule, specifically citing Nasdaq Listing Rule 5550(a)(2).
What each sentence states
“On November 19, 2026, the company received a notice from Nasdaq concerning its stock exchange listing.”
- Item 3.01 of Form 8-K covers notices about a company's stock exchange listing.
- Item 3.01: the exchange is Nasdaq.
- Item 3.01: the company received the exchange's notice on November 19, 2026.
“In the notice, Nasdaq states that the company does not meet a listing rule, specifically citing Nasdaq Listing Rule 5550(a)(2).”
- Item 3.01: the exchange is Nasdaq.
- Item 3.01: what it reports: the exchange says the company does not meet a listing rule.
- Item 3.01: the rule cited is Nasdaq Listing Rule 5550(a)(2).
- Item 3.01: the company received the exchange's notice on November 19, 2026.
Item 3.01
Stock exchange listing notice
-
Exchange
Nasdaq
From the filing
Source
“On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
Read by code from this sentence of the filing. -
What it says
The company does not meet a listing rule
From the filing
Source
“On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
Read by code from this sentence of the filing. -
Rule cited
Nasdaq Listing Rule 5550(a)(2)
From the filing
Source
“On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
Read by code from this sentence of the filing. -
Notice date
November 19, 2026
From the filing
Source
“On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).”
Read by code from this sentence of the filing.
Not investment advice.Read the filing on SEC.gov
Facts read from the filing's own text; a fact the filing does not state clearly is left out. All documents of this filing on SEC.gov.